FDA aims to approve more drugs based on early clinical data
Cancer drugs that cause tumours to shrink are considered likely to confer a meaningful clinical benefit, such as survival
Author
Men more likely to develop serious heart condition, infective endocarditis, as women: Study
The new study allows prevention measures to be targeted at those individuals most at risk of developing IE
FDA OKs Mylan’s biosimilar of Roche cancer drug Herceptin
Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision
Can Indian Pharma Inc find its lost mojo?
Ashish Prasad, Partner, Economic Laws Practice, Indian Pharma Inc will need to take stock of the current situation and chalk out a…
Policy experiences of 2017 for pharma sector
Krishna Sarma, Managing Partner of Corporate Law Group, gives an insight about the need to take positive learnings from the…
Pharma trends in 2018 and beyond
Anil Khanna, Partner, Wisdomsmith Advisors, gives an insight about pharma trends in 2018 and how the sector can go forward by…
Tracking biosimilar trends
In an insightful article, Debayan Ghosh, President & Founder, Epygen Biotech, highlights that biosimilars bear the potential…
Poised for a strong growth
Gaurav Agarwal, Director, Singhi Advisors, throws light on the trends in the new year and opines that Indian pharma companies…
Digitech: Revolutionising healthcare
Vineet Singhal, Country Head, Shire India, touches on the trends predicted to change the healthcare industry in the next decade…
Ramping up R&D— Key to success
Rahul Dev, Vice President India, Datwyler, highlights that R&D is of key importance for pharma companies to leverage…